Nonlinear progression during the occult transition establishes cancer lethality

Abstract

<jats:title>ABSTRACT</jats:title> <jats:p>Cancer screening relies upon a linear model of neoplastic growth and progression. Yet, historical observations suggest that malignant progression is uncoupled from growth, which may explain the paradoxical increase in early-stage breast cancer detection without a dramatic reduction in metastasis. Here, we lineage trace millions of transformed cells and thousands of tumors using a cancer rainbow mouse model of HER2 (also known as ERBB2)-positive breast cancer. Transition rates from field cell to screen-detectable tumor to symptomatic tumor were estimated from a dynamical model of tumor development. Field cells were orders of magnitude less likely to transition to a screen-detectable tumor than the subsequent transition from screen-detectable tumor to symptomatic tumor. Our model supports a critical ‘occult’ transition in tumor development during which a transformed cell becomes a bona fide neoplasm. Lineage tracing and test by transplantation revealed that nonlinear progression during the occult transition gives rise to nascent lethal cancers at screen detection. Simulations illustrated how occult transition rates are a critical determinant of tumor growth and malignancy. Our data provide direct experimental evidence that cancers can deviate from the predictable linear progression model that is foundational to current screening paradigms.</jats:p>

Department

Description

Provenance

Subjects

Citation

Published Version (Please cite this version)

10.1242/dmm.052113

Publication Info

Ginzel, Joshua D, Henry Chapman, Joelle E Sills, Edwin J Allen, Lawrence S Barak, Robert D Cardiff, Alexander D Borowsky, Herbert Kim Lyerly, et al. (2025). Nonlinear progression during the occult transition establishes cancer lethality. Disease Models & Mechanisms, 18(3). 10.1242/dmm.052113 Retrieved from https://hdl.handle.net/10161/32130.

This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.

Scholars@Duke

Lawrence Simeon Barak

Associate Research Professor of Cell Biology
Lyerly

Herbert Kim Lyerly

George Barth Geller Distinguished Professor of Immunology
Snyder

Joshua Clair Snyder

Associate Professor in Surgery

I am the PI of the Cancer Initiation and Cancer Cell Behavior lab. Our research objective is to determine how cancer cells adapt and grow before cancer is diagnosed. Our lab is also part of the Center for Applied therapeutics where we share our models as tools for preclinical and translational research. To learn more about our research please visit the Cancer Initiation and Cancer Cell Behavior Lab's homepage.


Unless otherwise indicated, scholarly articles published by Duke faculty members are made available here with a CC-BY-NC (Creative Commons Attribution Non-Commercial) license, as enabled by the Duke Open Access Policy. If you wish to use the materials in ways not already permitted under CC-BY-NC, please consult the copyright owner. Other materials are made available here through the author’s grant of a non-exclusive license to make their work openly accessible.